NeuroDerm is a clinical-stage pharmaceutical company developing next-generation treatments for central nervous system (CNS) disorders that will make a clinically meaningful difference in patients’ lives. NeuroDerm’s technology enables new routes of administration for existing drugs that overcome their current deficiencies and achieve enhanced clinical efficacy.

NeuroDerm is the first to develop liquid levodopa (LD), the gold standard treatment for Parkinson’s disease, thus enabling for the first time continuous sub-cutaneous (SC) administration of this drug. By overcoming its biggest deficiency – short half life – NeuroDerm’s products should transform patients’ lives, offering them clinical benefits that can only be obtained today by undergoing highly invasive surgery.

Latest Updates

NeuroDerm CEO to Present at Upcoming Investor Conferences

CEO Oded S. Lieberman will present at the Jefferies Autumn 2015 Global Healthcare Conference in London and at the Oppenheimer 26th Annual Healthcare Conference taking place in New York. > Read More

NeuroDerm Announces Third Quarter 2015 Financial Results

Company to Host Conference Call and Webcast Today at 8:30 a.m. ET. > Read More

NeuroDerm Announces Streamlined U.S. Development Plan Following FDA Feedback on ND0612H and ND0612L for the Treatment of Parkinson’s Disease

Based on FDA input, NeuroDerm is not required to conduct its largest Phase III pivotal trial of 360 patients .> Read More

Our Solutions

NeuroDerm is developing a pipeline of products that address deficiencies in current treatments for the growing population of moderate to severe Parkinson’s disease patients. NeuroDerm is the first to develop a liquid formulation of levodopa/carbidopa (LD/CD). Based on this novel formulation, the company has developed a line of LD/CD products administered through a patch-pump or small belt pump to deliver a continuous, controlled dose of LD/CD. The LD/CD line of products includes: ND0612L for moderate Parkinson’s disease patients, ND0612H for severe Parkinson’s disease patients and ND0680 for the small subset of severe Parkinson’s disease patients whose symptoms have advanced to a more acute stage, requiring even higher doses of LD/CD.